retatrutide phase 2 trial Retatrutide: A Promising Option for Non-Diabetic Weight Loss in Clinical Trials Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon

What They Test Not all tested products are tested equally

Acute kidney injury: Sudden kidney failure, particularly in patients who become dehydrated from gastrointestinal side effects

Clinical Trials and Safety Data ClinicalTrials.gov - Search for BPC-157: Database of clinical research studies

People with certain medical conditions, such as severe kidney disease, heart failure, or specific electrolyte imbalances, may need to avoid these treatments

Clinical studies demonstrate onset of subjective arousal within 6090 minutes at therapeutic doses, with effects lasting 68 hours

Ask your healthcare provider to submit a prior authorization